Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: Yahoo! Finance
G&A Expenses : G&A expenses were down to $14.9 million for the full year 2023 from $15.8 million in 2022. Net Loss : ELEV reported a net loss of $7.9 million for Q4 2023, improving from a net loss of $19.0 million in Q4 2022. Financial Outlook : ELEV expects its current cash reserves to fund operations into Q4 2025. Warning! GuruFocus has detected 3 Warning Signs with ELEV. On March 6, 2024, Elevation Oncology Inc ( NASDAQ:ELEV ) released its 8-K filing , detailing the company's financial results for the fourth quarter and full year ended December 31, 2023. ELEV, an oncology company dedicated to developing targeted therapeutics for cancer treatment, has reported a year of strategic progress and financial management. Company Overview Elevation Oncology Inc is at the forefront of oncology, focusing on the development of targeted therapeutics for cancer treatment in genomically defined patient populations. With a lead program targeting neuregulin-1 (NRG1) fusions, ELEV is co
Show less
Read more
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024PR Newswire
- Merrimack Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
ELEV
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- ELEV's page on the SEC website